⇄ 

Übersetzung für 'dabigatran' von Englisch nach Deutsch

dabigatran [C25H25N7O3]

Dabigatran {n}pharm.

---

dabigatran etexilate [C34H41N7O5]

Dabigatranetexilat {n}pharm.

• Dabigatran {n} = dabigatran [C25H25N7O3]

• CES1 is responsible for the activation of many prodrugs such as angiotensin-converting enzyme (ACE) inhibitors, oseltamivir, and dabigatran.
• USA recommendations for those without cancer include anticoagulation (medication that prevents further blood clots from forming) with the DOACs dabigatran, rivaroxaban, apixaban, or edoxaban rather than warfarin or low molecular weight heparin (LMWH).
• Dabigatran is contraindicated in patients who have active pathological bleeding, since dabigatran can increase bleeding risk and can also cause serious and potentially life-threatening bleeds.
• Other drugs with adverse reactions include dabigatran etexilate, lamivudine, and vincristine.
• These direct Factor Xa inhibitors can be administered orally, as can dabigatran etexilate, which is a direct thrombin inhibitor.

• ... rivaroxaban, apixaban and dabigatran) drugs are being used more commonly.
• The risk with dabigatran is 30% greater than that with warfarin.
• Preclinical tests have found that Verseon's novel anticoagulant compounds prevent thrombosis while preserving platelet function, meaning they are associated with significantly lower bleeding times than other currently approved anticoagulants dabigatran, argatroban or apixaban.
• g. dabigatran, rivaroxaban, apixaban or edoxaban) in patients with atrial fibrillation (AF).
• Initial pricing (AWP) is $58,000 per reversal (800 mg bolus + 960 mg infusion, $3,300 per 100 mg vial) which is higher than reversal agents for other DOAC agents (idarucizumab for use in dabigatran reversal is $4,200 per reversal).

• Apixaban and other anticoagulants (dabigatran, edoxaban and rivaroxaban) appear equally effective as warfarin in preventing non-hemorrhagic stroke in people with atrial fibrillation and are associated with lower risk of intracranial bleeding.
• Currently, rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) are DOACs listed under Pregnancy Category C, and apixaban (Eliquis) is listed under Pregnancy Category B.